Acute Kidney Injury Market Size Forecast: How The Industry Is Expected To Grow From 2026 To 2030
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Acute Kidney Injury Market Size And Revenue Outlook Through 2030
The acute kidney injury market size has demonstrated robust growth in recent years. It is projected to expand from $5.72 billion in 2025 to $6.09 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.5%. Historically, the expansion can be credited to elements such as limited access to advanced renal care, a rising prevalence of comorbidities like diabetes and hypertension, expanding hospital infrastructure, the adoption of conventional dialysis techniques, and increasing awareness of aki complications.
The acute kidney injury market is anticipated to show significant expansion in the upcoming years, with projections indicating a rise to $7.78 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.3%. This expansion during the forecast period is propelled by advancements in renal replacement therapies, the development of innovative nephroprotective drugs, the proliferation of ambulatory surgical centers, an increased reliance on biomarkers for early detection, and the incorporation of AI-based monitoring systems within renal care. Prominent trends for this period include a greater adoption of dialysis and drug therapies, the increasing global occurrence of acute kidney injury, a heightened focus on early diagnosis and biomarker development, wider applications of urinary implants, and the integration of minimally invasive techniques in AKI management.
Get A Free Sample Report With In-Depth Market Insights:
Acute Kidney Injury Market Growth Momentum: What Factors Are Shaping Demand?
The expanding occurrence of diabetes is anticipated to stimulate the advancement of the acute kidney injury market. Diabetes describes a collection of metabolic ailments distinguished by elevated blood sugar concentrations, which occur either because the body cannot generate adequate insulin or because cells do not react correctly to insulin. The escalating incidence of diabetes is propelled by elements such as increasing obesity rates, poor diets, sedentary lifestyles, an aging demographic, and better awareness and diagnostic methods. Acute kidney injury initiates metabolic and inflammatory modifications that can impact insulin resistance and glucose homeostasis, indicating a complex interaction that might affect the progression and management of diabetes. For instance, in March 2024, data from the Office for Health Improvement & Disparities, a UK-based government department, indicated that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Hence, the greater prevalence of diabetes is fueling the expansion of the acute kidney injury market.
Acute Kidney Injury Market Segment Analysis And Revenue Potential
The acute kidney injury market covered in this report is segmented –
1) By Injury: Pre-Renal Kidney Injury, Post-Renal Kidney Injury, Intrinsic Kidney Injury
2) By Treatment Type: Renal Replacement Therapy (RRT), Pharmacological Management, Supportive and Conservative Management, Obstruction-Relief Interventions
3) By End User: Hospitals, Dialysis Centers, Specialty Clinics, Other End Users
Subsegments:
1) By Pre-Renal Kidney Injury: Hypovolemia, Heart Failure-Related Injury, Sepsis-Induced Injury, Renal Artery Stenosis, Hepatorenal Syndrome
2) By Post-Renal Kidney Injury: Ureteral Obstruction, Bladder Outlet Obstruction, Prostate Enlargement (Benign Prostatic Hyperplasia), Kidney Stones, Tumors Affecting Urinary Tract
3) By Intrinsic Kidney Injury: Acute Tubular Necrosis (ATN), Acute Interstitial Nephritis (AIN), Glomerulonephritis, Vasculitis, Rhabdomyolysis-Induced Injury
Acute Kidney Injury Market Trends Redefining Industry Growth
Leading firms within the acute kidney injury (AKI) sector are prioritizing securing regulatory authorizations to expand their product ranges and introduce innovative therapeutic solutions. Such approvals signify the formal permission extended by regulatory organizations like the FDA or EMA, enabling a product’s commercialization and sale once it satisfies rigorous safety, effectiveness, and quality criteria. An example of this is Mission Therapeutics Ltd., a UK biotechnology firm, which obtained FDA clearance in December 2023 to commence a Phase II clinical trial for its primary compound, MTX652. This compound is designed to treat acute kidney injury (AKI) in individuals facing high risk after undergoing cardiac surgery. MTX652 is engineered to address crucial mechanisms implicated in kidney damage and regeneration, with goals of mitigating inflammation, averting additional renal harm, and fostering healing. A distinctive aspect of this trial is its concentration on utilizing innovative therapeutic approaches to tackle the fundamental molecular origins of AKI, potentially providing more efficacious treatment alternatives than current methods. The upcoming Phase II trial will assess MTX652’s safety profile, effectiveness, and pharmacokinetic properties, thereby furnishing vital information that could pave the way for wider clinical application and future authorization.
Acute Kidney Injury Market Key Players Shaping Industry Direction
Major companies operating in the acute kidney injury market are Fresenius Medical Care AG & Co. KGaA, Baxter International Inc., B. Braun Melsungen AG, Nipro Corporation, Nikkiso Co. Ltd., Asahi Kasei Medical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Quark Pharmaceuticals Inc., Kringle Pharma Inc., Aptabio Therapeutics Inc., AM-Pharma B.V., Arch Biopartners Inc., Guard Therapeutics International AB
View The Full Acute Kidney Injury Market Report:
Acute Kidney Injury Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the acute kidney injury market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute kidney injury market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
